1	2	3	4	
3	Duphar Interfran Ltd.	Dec., 1982	1005.10	
		Dec., 1983	1215.36	
		Dec., 1984	1463.79	
4	Astra-IDL	June, 1982	363.03	
		June, 1983	603.56	
		June, 1984	819.04	
5	U.S. Vitamins (India) Ltd. . . .	Sept., 1981	576.29	
		Sept., 1982	679.37	
		Sept., 1983	662.67	
6	Ms Glaxo Labs.	June, 1983 June, 1984	11409.41 11830.75	
		June, 1985	14325.54	
7	Merek Sharp and Dohme now Merind.	Dec., 1981	1683.61	Includine
		Dec., 1982	1681.90	Processing charge
		Dec., 1983	1385.40	
8	Parke Davis (I) Ltd.	Nov., 1982	2497·77	
		Nov., 1983	2590·98	
		Nov., 1984	2773·80	
9	Phizer Ltd.	Nov., 1982	5404·77	
		Nov., 1983	5207 08	
		Nov., 1984	5690 22	
10	Infar (India) Ltd.	Dec., 1983	1414.46	
		Dec., 198	1556.05	
		Dec., 1984	1648.31	
11	Sandoz (I) Ltd.	Dec., 1983	6239.93	
		Dec., 1984	6891·45	

Manufacture of Erythomycin by Abbott Laboratories

1512. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to state:

(a) whether Abbott Laboratories is licenced to produce Erythomycin and Its salts;

(b) if so, the licenced capacity of each and production during the last three years, year-wise;

(c) whether any quantity of Erythomycin and its salts was procured locally by this company;

(d) if so, the quantity procured during the last three years, year-wise, the quantity and purchase price per K.g. alongwith the name of surce of procurement;

(e) names of the formulations based on these drugs being manufactured and what was the total sales turnover of these formulations during the last three years, year-wise;

(f) what was the price fixed for each of these drugs and what was the price taken in fixation of their formulation prices under Drugs Price Contorl Order, 1979; and

(g) what was the total sales turnover of formulations of this company and percentage of overall profitability during last three years, year-wise?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) No, Sir.

(b) Does not arise.

(c) Yes, Sir.

(d) Details to the extent available are furnished in the attached statement.

(c) M/s. Abbott Labs are manufacturing Erthromycin 100 mg. tablets, 250 mg. tablets and 500 mg. tablets based on Erythormycin Stearate and Erythromycin Granules based on Erythromycin Ethyl Succinate. The sales turnover of these formulations for the last three years are furnished below:-

Year	Sales turnover of formulations based on Erythromycin and its Salts. (Rs. in Lakhs)
1982 . . .	427·79
1983 . . .	613·58
1984 . . .	624·13

(f) The price of Erythromycin stearate fixed under Drugs (Prices Control) Order, 1979 is Rs. 1642 per kg and the formulation prices are now based on the same price. Price has not been fixed for Erythromycin Ethyl Succinate under the said order. Formulation prices of Erythromycin Ethyl Succinate are based on landed cost of import which varies from time to time.

(g) Details are given below:-

Year	Total Sales Turnover (Rs. lacs)	Overall pre-tax profit (Rs. lacs)	Percentage pre-tax profit of sales turnover
Year ending Nov., 1992 .	1275·37	51·13	4·01
Year ending Nov., 1983 .	1528·01	71·07	4·65
Year ending Nov., 1984 .	1517·45	40·28	2·65

Statement

Sl. No.	Name of the Drug	Year	Quantity procured (in rupees)	Price of procurement (in rupees)	Source of procurement
1.	Erythromycin .	1982	2798	1300+ Taxes	Themis Pharmaceuticals
			10498	1300+ Taxes	Chemifime
		1983	2349	1300+ Taxes	Themis Pharmaceuticals

1	2	3	4	5	6
		11662	1300+	Taxes	Chemifine
	1984	1050	1300+	Taxes	Themis Pharmaceuticals
		13102	1300+	Taxes	Chemifine
2. Erythromycin Ethyl Succinate	1982	1192 545	2704 2048		Abbott Chemicals Puertorico. State Trading Corporration.
	1983	1860	2929		Abbott Chemicals is Puertorico
	1984	2000	3140		Do.

Hindustan Antibiotics Limited, Pune

1513. SHRI KAILASH PATI MISHRA:
SHRI LAL K. ADVANI.
SHRI SHANKER SINH VAGHELA:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that about Rs. 30 crores were spent recently on the expansion and modernisation of the penicillin, Ampicillin and Streptomycin plants of the Hindustan Antibiotics Limited, Pune;

(b) whether it is also a fact that prices of these products have been increased and the production thereof has come down;

(c) if so, what are the reasons thereof;

(d) whether the projects are made on loan licence basis from outside parties keeping the modern imported plant for capsules, tablets and syrus idle and thus undergoing losses and even locally procured products are not tested for quality control; and

(e) if so, what are the reasons thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The total expenditure on expansion and modernisation of Penicillin, Ampicillin and Streptomycin plants of Hindustan Antibiotics Limited (HAL) was Rs. 12.35 crores as under:

	(Rs. in crores)
(i) Penicillin expansion; .	2·95
(ii) Ampicillin expansion .	3·15
(iii) Streptomycin expansion .	6·26
	12·35

(b) and (c) Prices of Penicillin and Streptomycin were last revised in July| August 1982 and that of Ampicillin in September, 1983. Since then, there has been no revision in the prices of these products except interim price increase by Rs. 63.29 per BU allowed with effect from 13-9-1985 in respect of Procaine Penicillin bulk consequent upon increase in the price of Procaine Hydrochloride.

The shortfall in HAL's production of these drugs was mainly due to market constraints and technological problems.

(d) and (e) Some products are got manufactured on loan licence basis in exigencies such as (i) where the items are not in HAL's production range and (ii) capacity contraints and tight schedule of supply. Quality of products manufactured